Pliant Therapeutics Inc
$ 1.10
0.92%
22 Jul - close price
- Market Cap 67,493,000 USD
- Current Price $ 1.10
- High / Low $ 1.12 / 1.05
- Stock P/E N/A
- Book Value 2.69
- EPS -1.88
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.26 %
- ROE -0.54 %
- 52 Week High 1.95
- 52 Week Low 1.05
About
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and markets new therapies for the treatment of fibrosis and related diseases in the United States. The company is headquartered in South San Francisco, California.
Analyst Target Price
$2.50
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-11 | 2026-03-11 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-03-03 | 2024-11-07 | 2024-08-07 | 2024-05-06 | 2024-02-27 | 2023-11-09 | 2023-08-09 |
| Reported EPS | -0.32 | -0.3539 | -0.43 | -0.71 | -0.92 | -0.82 | -0.95 | -0.92 | -0.78 | -0.69 | -0.7 | -0.7 |
| Estimated EPS | -0.358 | -0.4162 | -0.56 | -0.62 | -0.7469 | -0.9552 | -0.97 | -0.85 | -0.77 | -0.81 | -0.77 | -0.71 |
| Surprise | 0.038 | 0.0623 | 0.13 | -0.09 | -0.1731 | 0.1352 | 0.02 | -0.07 | -0.01 | 0.12 | 0.07 | 0.01 |
| Surprise Percentage | 10.6145% | 14.9688% | 23.2143% | -14.5161% | -23.1758% | 14.1541% | 2.0619% | -8.2353% | -1.2987% | 14.8148% | 9.0909% | 1.4085% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.33 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PLRX
2026-07-13 23:42:21
This article reports on a Form 4 filing for Pliant Therapeutics Inc (PLRX) for July 13. Form 4s detail changes in beneficial ownership of company stock by insiders. The article, however, does not provide specific details from the Form 4 filing itself beyond noting its existence.
2026-07-13 21:10:15
Pliant Therapeutics has announced the appointment of Flavia Borellini, Ph.D., and Robert Iannone, M.D., M.S.C.E., to its Board of Directors. These appointments are expected to strengthen the company's strategic leadership as it continues to advance its therapeutic pipeline.
2026-07-13 20:42:21
Pliant Therapeutics director Borellini Flavia has filed an initial statement of beneficial ownership (Form 3) as a director according to an SEC filing. The filing indicates no equity transactions or derivative positions, solely disclosing her insider status. This is a neutral filing, providing an initial disclosure without detailing current holdings or trading activity.
2026-07-13 20:42:21
Pliant Therapeutics, Inc. (PLRX) director Robert Iannone has submitted an initial statement of beneficial ownership on Form 3. The filing indicates no reported transactions such as purchases, sales, or derivative exercises by Iannone. This Form 3 filing serves to officially disclose Iannone's beneficial ownership as a director of the company.
2026-07-13 20:42:21
Pliant Therapeutics (NASDAQ: PLRX) has granted 60,000 stock options to director Robert Iannone on July 9, 2026. The options have an exercise price of $1.13 per share and will expire on July 9, 2036. The vesting schedule dictates that 1/36th of the options will vest monthly, contingent on Iannone's continuous service to the company.
2026-07-13 20:42:21
Pliant Therapeutics (PLRX) has granted 60,000 stock options to director Flavia Borellini. The options, with an exercise price of $1.13 per share and an expiration date of July 9, 2036, will vest monthly over a 36-month period, contingent on her continued service. This grant is a compensatory award and was reported in a Form 4 SEC filing.
